Israeli biotech Pluristem has been awarded two new patents in Hong Kong for two products – mesenchymal stem cells for the treatment of skeletal muscle damage or injury, and adherent cells to treat Critical Limb Ischemia and connective tissue regeneration.
Stem cell treatments for Asia
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.